FA
NKGN

Fountainhead AM’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Fountainhead AM’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,911
Closed -$145K – 83
2022
Q3 		$145K Buy
+14,911
New +$145K 0.07% 73

Other funds holding NKGN

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

Fountainhead AM's NKGN Position: Q4 2022 in Review

Fountainhead AM sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2022, closing a stake of 14,911 shares — an estimated $145K sold.

Fountainhead AM first reported a position in NKGN in Q3 2022 and held it in 1 quarter. The position peaked at $145K in Q3 2022. 60 funds tracked by Wall St. Rank hold NKGN as of Q4 2022.

  • Fountainhead AM reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Fountainhead AM sold 14,911 NKGen Biotech, Inc. Common Stock shares in Q4 2022, an estimated $145K.
  • Fountainhead AM first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Fountainhead AM's NKGen Biotech, Inc. Common Stock position peaked at $145K in Q3 2022.
  • 60 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2022.

Based on Fountainhead AM's 13F filing for Q4 2022, filed 9 Feb 2023.